First-line Systemic Therapy for Metastatic Non-small-cell Lung Cancer - A Review

Journal of Experimental and Clinical Medicine

Volumn 3, Issue 3, 2011, Pages 116-120

  Chen, Yuh Min ^a,b   Whang Peng, Jacqueline ^b,c   Chen, Chien Ming ^b,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chemotherapy; Non small cell lung cancer (NSCLC); Targeted therapy

Indexed keywords

AFATINIB; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM COMPLEX; VANDETANIB;

BONE MARROW SUPPRESSION; CANCER SURVIVAL; DIARRHEA; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG PENETRATION; DRUG RESPONSE; DRUG SAFETY; EXON; GENE MUTATION; HUMAN; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PATIENT PREFERENCE; PNEUMONIA; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; REVIEW; SYSTEMIC THERAPY; THROMBOCYTOPENIA; VOMITING; WILD TYPE;

EID: 79958844961     PISSN: 18783317     EISSN: 18783325     Source Type: Journal    
DOI: 10.1016/j.jecm.2011.04.008     Document Type: Review

References (53)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics 2009. CA Cancer J Clin 2009, 59:225-249.
2. Chen Y.M., Chao J.Y., Tsai C.M., Shiau C.Y., Liang M.J., Yen S.H., Perng R.P. Treatment of non-small-cell lung cancer: the Chinese experience in a general teaching hospital. J Chin Med Assoc 2000, 63:459-466.
3. Alberg A.J., Ford J.G., Samet J.M. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:29S-55S.
4. Alberg A.J., Brock M.V., Samet J.M. Epidemiology of lung cancer: looking to the future. J Clin Oncol 2005, 23:3175-3185.
5. Carney D.N., Hansen H.H. Non-small-cell lung cancer - stalemate or progress?. N Engl J Med 2000, 343:1261-1262.
6. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., Johnson D.H. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
7. Fathi A.T., Brahmer J.R. Chemotherapy for advanced stage non-small cell lung cancer. Semin Thorac Cardiovasc Surg 2008, 20:210-216.
8. Berhoune M., Banu E., Scotte F., Prognon P., Oudard S., Bonan B. Therapeutic strategy for treatment of metastatic non-small cell lung cancer. Ann Pharmacother 2008, 42:1640-1652.
9. Scagliotti G.V., Ceppi P., Novello S., Papotti M. Chemotherapy treatment decisions in advanced non-small cell lung cancer based on histology. Edu Book Am Soc Clin Oncol 2009, 27:431-435.
10. Scagliotti G., Brodowicz T., Shepherd F.A., Zielinski C., Vansteenkiste J., Manegold C., Simms L., et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011, 6:64-70.
11. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
12. Mitsudomi T., Kosaka T., Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol 2006, 11:190-198.
13. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., Sunpaweravong P., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Eng J Med 2009, 361:947-957.
14. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., Gemma A., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
15. Zhou C., Wu Y.L., Chen G., Feng J., Liu X., Wang C., Zhang S. Efficacy results from the randomized phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (PTS) with EGFR activating mutations. Ann Oncol 2010, 21(Suppl. 8):LBA13. [Abstract].
16. Takano T., Fukui T., Ohe Y., Tsuta K., Yamamoto S., Nokihara H., Yamamoto N., et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 2008, 26:5589-5595.
17. Delbaldo C., Michiels S., Syz N., Soria J.C., Le Chevalier T., Pignon J.P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small cell lung cancer: a meta-analysis. JAMA 2004, 292:470-484.
18. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., Zhu J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
19. Goffin J., Lacchetti C., Ellis P.M., Ung Y.C., Evans W.K. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 2010, 5:260-274.
20. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., Serwatowski P., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
21. Fallowfield L.J., Harper P. Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer. Lung Cancer 2005, 48:365-377.
22. Dranitsaris G., Cottrell W., Evans W.K. Cost-effectiveness of chemotherapy for non-small-cell lung cancer. Curr Opin Oncol 2002, 14:375-383.
23. Scagliotti G.V., De Marinis F., Rinaldi M., Crino L., Gridelli C., Ricci S., Matano E., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
24. Zatloukal P., Petruzelka L., Zemanova M., Kolek V., Skrickova J., Pesek M., Fojtu H. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003, 41:321-331.
25. Park J.O., Kim S.W., Ahn J.S., Suh C., Lee J.S., Jang J.S., Cho E.K., et al. Phase III trial of two versus four additional cycles in patients who are non progressive after two cycles of platinum based chemotherapy in non-small-cell lung cancer. J Clin Oncol 2007, 25:5233-5239.
26. von Plessen C., Bergman B., Andresen O., Bremnes R.M., Sundstrom S., Gilleryd M., Stephens R., et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 2006, 95:966-973.
27. Fidias P.M., Dakhil S.R., Lyss A.P., Loesch D.M., Waterhouse D.M., Bromund J.L., Chen R., et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:591-598.
28. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., Wu Y.L., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
29. Brodowicz T., Krzakowski M., Zwitter M., Tzekova V., Ramlau R., Ghilezan N., Ciuleanu T., et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006, 52:155-163. Central European Cooperative Oncology Group CECOG.
30. Westeel V., Quoix E., Moro-Sibilot D., Mercier M., Breton J.L., Debieuvre D., Richard P., et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 2005, 97:499-506. French Thoracic Oncology Collaborative Group (GCOT).
31. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczésna A., Juhász E., Esteban E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
32. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., Natale R.B., et al. Gefitinib (ZD1839) in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial (INTACT 1). J Clin Oncol 2004, 22:777-784.
33. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., Scagliotti G., et al. Gefitinib (ZD1839) in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial (INTACT 2). J Clin Oncol 2004, 22:785-794.
34. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., Kris M.G., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (osi-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892-5899.
35. Gatzemeier U., Pluzanska A., Szczesna A., Kaukel E., Roubec J., De Rosa F., Milanowski J., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the Tarceva lung cancer investigation trial. J Clin Oncol 2007, 25:1545-1552.
36. Mok T., Wu Y.L., Yu C.J., Zhou C., Chen Y.M., Zhang L., Ignacio J., et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:5080-5087.
37. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., Vynnychenko I., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 2009, 373:1525-1531.
38. Gatzemeier U., von Pawel J., Vynnychenko I., Zatloukal P., de Marinis F., Eberhardt W.E.E., Paz-Ares L., et al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol 2011, 12:30-37.
39. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., Leighl N., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27:1227-1234.
40. Crinò L., Dansin E., Garrido P., Griesinger F., Laskin J., Pavlakis N., Stroiakovski D., et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010, 11:733-740.
41. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., Langer C.J., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
42. Hainsworth J.D., Fang L., Huang J.E., Karlin D., Russell K., Faoro L., Azzoli C. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. J Thorac Oncol 2011, 6:109-114.
43. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., Gatzemeier U., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
44. Murray S., Dahabreh I.J., Linardou H., Manoloukos M., Bafaloukos D., Kosmidis P. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J Thorac Oncol 2008, 3:832-839.
45. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., Seto T., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
46. Gandhi J., Zhang J., Xie Y., Soh J., Shigematsu H., Zhang W., Yamamoto H., et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS ONE 2009, 4:e4576. doi:10.1371/journal.pone.0004576.
47. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
48. Jackman D.M., Holmes A.J., Lindeman N., Wen P.Y., Kesari S., Borras A.M., Bailey C., et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006, 24:4517-4520.
49. Katayama T., Shimizu J., Suda K., Onozato R., Fukui T., Ito S., Hatooka S., et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009, 4:1415-1419.
50. Togashi Y., Masago K., Fukudo M., Terada T., Ikemi Y., Kim Y.H., Fujita S., et al. Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. J Thorac Oncol 2010, 5:601-605.
51. Fan W.C., Yu C.J., Tsai C.M., Huang M.S., Lai C.L., Hsia T.C., Tien Y.J., et al. Different efficacies of erlotinib and gefitinib in Taiwanese patients with advanced non-small cell lung cancer: a retrospective multi-center study. J Thor Oncol 2011, 6:148-155.
52. Dempke W.C.M., Suto T., Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer 2010, 67:257-274.
53. Somaiah N., Simon G.R. Molecular targeted agents and biologic therapies for non-small cell lung cancer. J Thor Oncol 2010, 5(Suppl. 6):S434-S454.